A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma

Trial Profile

A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2017

At a glance

  • Drugs Riluzole (Primary) ; Sorafenib (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
    • 01 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top